266 related articles for article (PubMed ID: 29524334)
1. In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.
Dietis N; Niwa H; Tose R; McDonald J; Ruggieri V; Filaferro M; Vitale G; Micheli L; Ghelardini C; Salvadori S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
Br J Pharmacol; 2018 Jul; 175(14):2881-2896. PubMed ID: 29524334
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505).
Dietis N; McDonald J; Molinari S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
Br J Anaesth; 2012 Feb; 108(2):262-70. PubMed ID: 22194444
[TBL] [Abstract][Full Text] [Related]
3. Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.
Schuster DJ; Metcalf MD; Kitto KF; Messing RO; Fairbanks CA; Wilcox GL
Br J Pharmacol; 2015 Jan; 172(2):642-53. PubMed ID: 24827408
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
[TBL] [Abstract][Full Text] [Related]
6. Prolonged morphine treatment alters δ opioid receptor post-internalization trafficking.
Ong EW; Xue L; Olmstead MC; Cahill CM
Br J Pharmacol; 2015 Jan; 172(2):615-29. PubMed ID: 24819092
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
8. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.
Khroyan TV; Wu J; Polgar WE; Cami-Kobeci G; Fotaki N; Husbands SM; Toll L
Br J Pharmacol; 2015 Jan; 172(2):668-80. PubMed ID: 24903063
[TBL] [Abstract][Full Text] [Related]
9. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
Negri L; Improta G; Lattanzi R; Potenza RL; Luchetti F; Melchiorri P
Br J Pharmacol; 1995 Dec; 116(7):2931-8. PubMed ID: 8680727
[TBL] [Abstract][Full Text] [Related]
10. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
11. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
12. Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration.
Stevenson GW; Giuvelis D; Cormier J; Cone K; Atherton P; Krivitsky R; Warner E; St Laurent B; Dutra J; Bidlack JM; Szabò L; Polt R; Bilsky EJ
Psychopharmacology (Berl); 2020 Apr; 237(4):1195-1208. PubMed ID: 31912192
[TBL] [Abstract][Full Text] [Related]
13. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
14. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
[TBL] [Abstract][Full Text] [Related]
15. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
16. Targeting multiple opioid receptors - improved analgesics with reduced side effects?
Günther T; Dasgupta P; Mann A; Miess E; Kliewer A; Fritzwanker S; Steinborn R; Schulz S
Br J Pharmacol; 2018 Jul; 175(14):2857-2868. PubMed ID: 28378462
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
Abul-Husn NS; Sutak M; Milne B; Jhamandas K
Br J Pharmacol; 2007 Jul; 151(6):877-87. PubMed ID: 17502848
[TBL] [Abstract][Full Text] [Related]
18. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
19. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
[TBL] [Abstract][Full Text] [Related]
20. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]